Drug intelligence / Profile preview

HR17020

Development stage: Unknown
Lead developer: Jiangsu Hengrui Medicine
Modality: Small Molecules
Administration: Subcutaneous

Overview

HR17020 is a subcutaneous formulation of apixaban, a direct factor Xa inhibitor, developed by Jiangsu Hengrui Medicine. Apixaban is a highly selective, reversible, and direct inhibitor of free and clot-bound factor Xa, as well as prothrombinase activity. By inhibiting factor Xa, the drug decreases thrombin generation and thrombus formation. While apixaban is traditionally administered orally (marketed as Eliquis), HR17020 is being developed for subcutaneous administration, which may offer clinical advantages in specific patient populations or settings. It is currently in Phase 1 clinical development for the prevention and treatment of venous thromboembolism (VTE).

Other names: subcutaneous apixaban

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on HR17020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR17020.

Explore the full profile